secwatch.observer — SEC 8-K summary
======================================

Issuer:     IMMUCELL CORP /DE/ (ICCC)
CIK:        0000811641
Form:       8-K
Filed at:   2024-05-14T23:59:59+00:00
Accession:  0001213900-24-042926
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ImmuCell Q1 2024: Record sales $7.3M (+111% YoY); net loss narrows; FDA delays Re-Tain
--------------------------------------------------------------------------------

- Product sales of $7.3M, up 111% YoY from $3.4M; all-time quarterly record.
- Net loss improved to $438k ($0.06/sh) vs $2.3M loss ($0.30/sh) a year ago.
- Gross margin rose to 32% from 9%, driven by recovery from 2023 contamination events.
- Production output annualized to $28.7M (~96% of $30M capacity); backlog $9.1M.
- FDA issued Incomplete Letter for Re-Tain CMC; requires contract manufacturer inspection resolution before resubmission.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/811641/000121390024042926/0001213900-24-042926-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/811641/000121390024042926/ea0206072-8k_immucell.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-042926

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer